Contributor Page
Smart & Biggar/Fetherstonhaugh
Email  |  Website  |  Articles
Contact Details
Tel: +1 416 5935514
Fax: +1 416 5911690
1100-150 York Street
ON M5H 3S5
By Mark Evans, Nora Labbancz
Non-Canadian hoteliers have reason for celebration following the release of the Federal Court of Canada's anticipated decision in Hilton Worldwide Holding LLP v Miller Thomson LLP, 2018 FC 895
By Smart & Biggar/Fetherstonhaugh
PMNOC Proceedings.
By Tierney Deluzio
On August 20, 2018, the Federal Court dismissed Valeant's PMNOC application regarding Ranbaxy's bupropion extended-release tablets and Patent No. 2,524,300.
By Mark Evans, David Schwartz
NAFTA came into force on January 1, 1994, creating what was at that time the largest free-trade region in the world.
By Katie Lee
Drug shortages are an important issue in the health care system that Health Canada and the industry have been actively trying to address.
By Urszula Wojtyra
On August 22, 2018, the Minister of Health tabled the 2017 Annual Report with the Clerks of the House of Commons and the Senate.
By Brandon Heard
On August 9, 2018, the Supreme Court of Canada denied Sobeys' application for leave to appeal (docket no. 37864) from the Alberta Court of Appeal's decision in a dispute regarding the Alberta College of Pharmacists' policy ...
By Katie Lee, Urszula Wojtyra
As previously reported, the amended Patented Medicines (Notice of Compliance) Regulations came into force on September 21, 2017, heralding significant changes to the landscape for pharmaceutical companies in Canada.
By Nancy Pei, Daphne Lainson
September 21, 2018 marked the first anniversary of the certificate of supplementary protection (CSP) regime.
By Daphne Lainson
Patentees take note: September 21, 2018 marks the first anniversary of the Certificate of Supplementary Protection (CSP) regime in Canada, and it also marks the end of the transitional period for securing a CSP.
By Urszula Wojtyra
This is a new consolidated publication that will communicate updates to CADTH's drug review process.
By Andrew Mandlsohn
Patented Medicine Prices Review Board releases August 2018 NEWSletter.
By Andrew Mandlsohn
Participants can provide their feedback online until September 28, 2018 or in writing to the Council.
By Abigail Smith
Health Canada announced it will move forward with Phase III of its prescription drug product transparency initiatives.
By Andrew Mandlsohn
The Report includes information regarding trends in listing on the Patent Register and the Register of Innovative Drugs, as well as related court activity.